https://www.selleckchem.com/pr....oducts/colivelin.htm
Targeting several top Trem1 inflammatory signatures inhibits the proliferation of pre-leukemic HSCs and LSCs. Collectively, our observations uncover previously unknown expression and function of TREM1 in malignant stem cells, and identify TREM1 as a driver of leukemogenesis.Among patients with chronic lymphocytic leukemia (CLL) with deletion 17p (del[17p]), evidence from clinical trials for the effectiveness of single-agent ibrutinib as first-line (1L) therapy is limited. This retrospective analysis compared real-world clinical outcom
Me gusta
Comentario
Compartir
